Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Sunday, April 22, 2012
Gilead's Hepatitis C Drug Poised To Reach The Market As One Of The First 'All Oral' Combinations
Stronger than expected results emerged from both the Electron and Quantum studies, making it almost certain that the potent nucleotide analogue will form the backbone of the first all-oral hepatitis C therapy to reach the market. Gilead shares soared 14% to $53.31 in early trade.